FDA approves Johnson & Johnson treatment for depressive disorder
Johnson & Johnson said Nov. 6 that the Food and Drug Administration approved CAPLYTA (lumateperone) as a supplemental therapy with antidepressants for the treatment of major depres…
More from New Jersey Business
New Jersey Chamber of Commerce
Statement: Sherrill administration should have delayed New Jersey's new independent contractor regulations
New Jersey Business
•
Oct 1, 2026
Jersey Digs
New Report Says N.J. Needs More Affordable Homes for Sale, Not Just Buyer Assistance
New Jersey Business
•
Sep 30, 2026
Jersey Digs
100,000 Square Foot Expansion Breaks Ground at Liberty Science Center
New Jersey Business
•
Sep 28, 2026
Jersey Digs
Panoramic Manhattan Views and a Private Terrace Define This Avora Residence
New Jersey Business
•
Sep 22, 2026
New Jersey Chamber of Commerce
New Jersey cannot afford to send mixed signals to business
New Jersey Business
•
Sep 14, 2026
Jersey Digs
Team Moza Debuts Casa One, Featuring 196 Rental Residences in Journal Square
New Jersey Business
•
Sep 4, 2026
Jersey Digs
Princeton Community Housing to Build Affordable Apartments on Former DPW Site
New Jersey Business
•
Sep 3, 2026
Jersey Digs
All-Affordable 113-Unit Development Moves Forward in Wayne
New Jersey Business
•
Aug 28, 2026